PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
A new lung cancer niche is a major focus of Asco, with China's Dizal perhaps boasting the most intriguing dataset.
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
Alkermes plays up responses in mucosal melanoma, but those hoping for an IL-2 renaissance might be disappointed.
The group still has its eye on accelerated approval, though genetic testing casts a long shadow.
177Lu-PSMA-617 shows impressive survival results in the Vision study, but early use will be key to fulfilling its potential.
But the space, a battle between Opdivo and Keytruda, is becoming extremely complex, and Bristol’s win is not unequivocal.
The long overdue advent of US cut-price oncology drugs is a major theme at this year’s Asco, and Junshi’s toripalimab leads the way.
Lynparza could become the first Parp inhibitor approved for adjuvant use, an Asco late-breaker reveals.